A lawsuit was filed on behalf of investors in IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) shares over alleged securities laws violations.

San Diego, CA -- (SBWire) -- 08/25/2017 --An investor, who purchased shares of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), filed a lawsuit over alleged violations of Federal Securities Laws by IntelliPharmaCeutics Intl Inc (USA).

Investors who purchased shares of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint the plaintiff alleges on behalf of purchasers of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) common shares between January 14, 2016 and July 26, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 14, 2016 and July 26, 2017, the defendants made false and/or misleading statements and/or failed to disclose that Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application ("NDA"), that the Company did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways, that the Company was not submitting sufficient data to support approval of the NDA, and that as a result, Defendants' statements about Intellipharmaceutics' business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Those who purchased shares of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com